Biosig Technologies (NASDAQ:STEX) CIO Mitchell Young Williams Sells 23,810 Shares

Biosig Technologies, Inc. (NASDAQ:STEX) CIO Mitchell Young Williams sold 23,810 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $1.05, for a total transaction of $25,000.50. Following the sale, the executive directly owned 3,013,838 shares of the company’s stock, valued at $3,164,529.90. This represents a 0.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mitchell Young Williams also recently made the following trade(s):

• On Friday, May 1st, Mitchell Young Williams sold 263,863 shares of Biosig Technologies stock. The stock was sold at an average price of $0.79, for a total transaction of $208,451.77.

Biosig Technologies Stock Performance

Shares of NASDAQ STEX traded down $0.19 during midday trading on Tuesday, reaching $1.19. The stock had a trading volume of 1,898,350 shares, compared to its average volume of 1,566,984. The firm has a 50 day simple moving average of $1.12. Biosig Technologies, Inc. has a twelve month low of $0.70 and a twelve month high of $14.11. The company has a market cap of $215.43 million, a price-to-earnings ratio of -0.12 and a beta of 1.85.

Biosig Technologies (NASDAQ:STEX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter.

Analyst Ratings Changes

Several research analysts have recently weighed in on STEX shares. Needham & Company LLC lowered their price objective on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. Weiss Ratings raised Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen downgraded Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.